Efficacy and safety of subcutaneous mosunetuzumab in combination with lenalidomide and as a monotherapy in Japanese patients with relapsed/refractory follicular lymphoma
Mosunetuzumab SC, in combination with lenalidomide and as monotherapy, demonstrated promising efficacy with a manageable safety profile in Japanese patients with R/R FL.
Authors
- D. Maruyama
- Koji Izutsu (ORCID: https://orcid.org/0000-0001-9129-8057)
- C. Mori
- Yuko Mishima (ORCID: https://orcid.org/0000-0002-9742-8470)
- Noriko Fukuhara (ORCID: https://orcid.org/0000-0003-2682-2179)
- Atsuko Kawasaki
- J. Kuroda
- K. Shimada
- Takeshi MIYAKE
- Shinichi Makita
- Nobuhiro Kanemura
Institutions
- Tohoku University (JP)
- Kyoto Prefectural University of Medicine (JP)
- National Cancer Centre Japan (JP)
- National Cancer Center (US)
- Gifu University Hospital (JP)
- Tokyo National Hospital (JP)
- Japanese Foundation For Cancer Research (JP)
- Nagoya University (JP)
- Kindai University (JP)
Publication Details
- Journal
- International Journal of Clinical Oncology
- Published
- 2026-01-12
- DOI
- https://doi.org/10.1007/s10147-025-02957-1
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chugai Pharmaceutical